<DOC>
	<DOCNO>NCT01351792</DOCNO>
	<brief_summary>The purpose present study demonstrate high efficacy small particle Foster® 100/6 ( two puff b.i.d . ) versus large particle Symbicort® 200/6 ( two inhalation b.i.d . ) , term residual volume reduction 12-week treatment period Chronic Obstructive Pulmonary Disease ( COPD ) patient .</brief_summary>
	<brief_title>A Study Patients With Chronic Obstructive Pulmonary Disease ( FAIR )</brief_title>
	<detailed_description>Chronic obstructive pulmonary disease ( COPD ) incurable , debilitate progressive disease fatal . The recent Global Burden Disease Study rank COPD 6th lead cause mortality 12th lead cause morbidity world-wide . Furthermore , trend use medical care resource indicate economic cost COPD continue rise direct relation age population , increase prevalence disease cost new exist medical public health intervention .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Male female patient age ≥ 40 year , sign Informed Consent form prior initiation studyrelated procedure applicable write informed consent obtain legal representative . 2 . Outpatients clinical diagnosis moderate severe COPD include : 1 . Smoking history least 10 pack year define [ ( number cigarette smoke per day ) x ( number year smoke ) ] / 20 , current exsmokers eligible . 2 . Regular use bronchodilator ( e.g . β2agonist , anticholinergic ) 2 month visit 1 . 3 . Postbronchodilator FEV1 &lt; 65 % predict normal value visit 1 . 4 . Postbronchodilator FEV1/FVC &lt; 0.7 visit 1 . 5 . An increase FEV1 &lt; 15 % &lt; 200 mL baseline follow administration 400 µg salbutamol visit 1 . 6 . Plethysmographic Functional Residual Capacity ( FRC ) &gt; 120 % predict normal value ( visit 1 visit 2 ) . 7 . A Baseline Dyspnoea Index ( BDI ) focal score less equal 10 ( visit 1 visit 2 ) . 3 . A cooperative attitude ability train proper use pMDI DPI ( Turbohaler® , inspiratory flowdriven , multidose powder inhaler ) inhaler . Main 1 . Diagnosis asthma clinically functionally relevant respiratory disorder ( COPD ) may interfere data interpretation accord investigator 's opinion . 2 . Clinically unstable concurrent disease : e.g . hyperthyroidism , diabetes mellitus endocrine disease ; significant hepatic impairment ; significant renal impairment ; cardiovascular disease ( e.g . coronary artery disease , hypertension , heart failure ) ; gastrointestinal disease ( e.g . active peptic ulcer ) ; neurological disease ; haematological disease ; autoimmune disorder , may impact evaluation result study accord investigator 's judgement . 3 . Patients COPD exacerbation and/or symptomatic infection airway require antibiotic therapy ( least 5 day ) 2 month prior screen study period . 4 . Patients treat depot corticosteroid 2 month precede visit 1 runin period . 5 . Major surgery previous 3 month trial may affect patient 's compliance study procedure ( e.g . plethysmography ) . 6 . Patients require chronic mechanical ventilation COPD .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>